Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC.

Trial Profile

Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 May 2018

At a glance

  • Drugs Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLAS
  • Sponsors SFJ Pharmaceuticals
  • Most Recent Events

    • 30 Apr 2018 According to a Pfizer media release, based on the independent Data Monitoring Committee recommendation, the company has decided to discontinue the trial.
    • 11 Apr 2018 Status changed from active, no longer recruiting to discontinued, as reported in a Pfizer media release.
    • 10 Apr 2018 According to a Pfizer media release, the company is planning to conduct additional analyses. Detailed efficacy and safety data from ATLAS will be submitted for presentation at a future medical meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top